TORII PHARMACEUTICAL CO., LTD., The Current Fiscal Year Ordinary Profit Revised Upward by 6%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Oct 31, 2024 3:00 pm JST Earnings

4551 TORII PHARMACEUTICAL CO., LTD. 【J-GAAP】

Earnings Report

TORII PHARMACEUTICAL CO., LTD. <4551> [TSE-P] announced its financial results after the market closed on October 31st (15:00). The ordinary profit (non-consolidated) for the cumulative third quarter of the fiscal year ending December 2024 (January to September) expanded to 4.68 billion yen, an increase of 41.4% compared to the same period last year.

In addition, the full-year ordinary profit has been revised upward by 6.3%, from the previous forecast of 6.4 billion yen to 6.8 billion yen (compared to 5.3 billion yen in the previous period), increasing the growth rate from 20.6% to 28.1%.

Based on the full-year plan announced by the company after the upward revision, our estimate of the ordinary profit for the July to December period (second half) is expected to increase by 11.7%, from the previous forecast of 3.41 billion yen to 3.81 billion yen (compared to 3.76 billion yen in the same period of the previous year), turning to a 1.4% increase in the ordinary profit outlook.

In the most recent three-month period, from July to September (3Q), the ordinary profit decreased to 1.7 billion yen, a 4.0% decrease compared to the same period last year. The operating profit margin decreased from 12.7% in the same period last year to 10.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	35,315	4,066	3,918	2,856	101.7	70.8	Oct 31, 2022	J-GAAP
Jan - Sep, 2023	39,132	3,211	3,315	2,368	84.3	62.5	Oct 31, 2023	J-GAAP
Jan - Sep, 2024	43,333	4,661	4,686	3,525	125.4	68.9	Oct 31, 2024	J-GAAP
YoY	+10.7%	+45.2%	+41.4%	+48.9%	+48.8%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024 Prev	32,391	3,159	3,415	2,579	91.7	60	Jul 31, 2024	J-GAAP
Jul - Dec, 2024 New	32,891	3,559	3,815	2,879	102.4	60	Oct 31, 2024	J-GAAP
Revision Rate	+1.5%	+12.7%	+11.7%	+11.6%	+11.6%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2024 Prev	60,700	6,300	6,400	4,800	170.8	120	Jul 31, 2024	J-GAAP
Dec, 2024 New	61,200	6,700	6,800	5,100	181.4	120	Oct 31, 2024	J-GAAP
Revision Rate	+0.8%	+6.3%	+6.3%	+6.3%	+6.2%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2023	28,939	3,525	3,764	3,033	108.0	70	Feb 9, 2024	J-GAAP
Jul - Dec, 2024 Guidance	32,891	3,559	3,815	2,879	102.4	60	Oct 31, 2024	J-GAAP
YoY	+13.7%	+1.0%	+1.4%	-5.1%	-5.1%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	48,896	5,540	5,537	3,944	140.4	100	Feb 10, 2023	J-GAAP
Dec, 2023	54,638	5,035	5,307	4,119	146.6	120	Feb 9, 2024	J-GAAP
Dec, 2024 Guidance	61,200	6,700	6,800	5,100	181.4	120	Oct 31, 2024	J-GAAP
YoY	+12.0%	+33.1%	+28.1%	+23.8%	+23.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2023	13,433	1,701	1,772	1,282	45.6	12.7	Oct 31, 2023	J-GAAP
Oct - Dec, 2023	15,506	1,824	1,992	1,751	62.3	11.8	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	13,451	1,383	1,166	878	31.3	10.3	Apr 26, 2024	J-GAAP
Apr - Jun, 2024	14,858	1,758	1,819	1,343	47.8	11.8	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	15,024	1,520	1,701	1,304	46.4	10.1	Oct 31, 2024	J-GAAP
YoY	+11.8%	-10.6%	-4.0%	+1.7%	+1.7%